Ceribell, Inc. (CBLL) AI Stock Analysis

• Market Cap: $428.83M
• Dividend Yield: N/A
• Average Volume (3M): 275.33K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.87
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 281
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.37
• Shares Outstanding: 37,095,690
• 10 Day Avg. Volume: 307,950
• 30 Day Avg. Volume: 275,331
• PEG Ratio: 1.93
• Price to Book (P/B): 4.22
• Price to Sales (P/S): 12.34
• P/FCF Ratio: -22.20
• Enterprise Value/Market Cap: 0.64
• Enterprise Value/Revenue: 3.33
• Enterprise Value/Gross Profit: 3.78
• Enterprise Value/Ebitda: -5.43
• 1Y Price Target: $23.50
• Price Target Upside: 103.29% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): -1.51
• Revenue Forecast (FY): $86.94M

• Rating: 51 Neutral
• Price Target: $11.00 ▼(-4.84% Downside)

Ceribell, Inc. shows strong revenue growth and strategic expansion efforts, which are positive indicators. However, the company's ongoing financial losses, negative cash flow, and bearish technical indicators present significant risks. The stock's valuation is also a concern due to its lack of profitability.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for Ceribell's products, enhancing market position and supporting long-term business expansion.

Market Opportunity

Targeting a $2 billion market opportunity positions Ceribell for substantial growth, leveraging its innovative technology to capture new segments.

Product Innovation

Continued innovation in EEG technology, such as the Delirium Study, strengthens Ceribell's competitive edge and supports long-term product relevance.

Negative Factors

Operating Expenses

Rising operating expenses could pressure profitability and cash flow, potentially hindering Ceribell's ability to sustain long-term growth.

Net Loss

Widening net losses indicate financial challenges, which may affect Ceribell's ability to invest in growth and innovation over time.

Cash Flow Management

Negative cash flow, despite improvements, suggests ongoing reliance on external funding, which can impact financial stability and flexibility.

Ceribell, Inc. Business Overview & Revenue Model

Company Description

Ceribell, Inc. (CBLL) is a healthcare technology company focused on transforming the management of epilepsy through its innovative seizure detection and monitoring solutions. Operating primarily in the medical device sector, Ceribell's core product is its FDA-cleared EEG monitoring system, which provides real-time data and insights for healthcare professionals to better manage and respond to seizures in patients. The company's mission is to improve patient outcomes and streamline the care process for individuals experiencing epilepsy and other seizure-related conditions.

How the Company Makes Money

Ceribell generates revenue primarily through the sale of its EEG monitoring devices and associated services. The company has established partnerships with hospitals and healthcare systems that utilize its technology in their neurology departments. Additionally, Ceribell may offer subscription-based services for data management and analysis, enhancing patient monitoring capabilities over time. Revenue is also driven by ongoing support, maintenance services, and potential future collaborations with pharmaceutical companies focused on epilepsy treatments. Furthermore, reimbursement from insurance providers for the use of their devices plays a significant role in the company's financial model.

Ceribell, Inc. Financial Statement Overview

Summary

Ceribell, Inc. is experiencing strong revenue growth and has improved its equity position significantly. However, the company is still operating at a loss, with negative cash flow and high operating expenses, indicating ongoing financial challenges.

Income Statement

Ceribell, Inc. shows solid revenue growth of 44.7% from 2023 to 2024, highlighting strong demand for their products. However, the company is operating at a loss with a negative net profit margin, and EBIT and EBITDA margins indicate inefficiencies. Gross profit margins are strong at approximately 86.7% for 2024, signifying good production cost management but are overshadowed by the high operating expenses.

Balance Sheet

The company's equity has significantly improved from negative to a strong positive position in 2024, indicating strong financial backing or recent capital infusion. The debt-to-equity ratio is low due to high equity, showcasing low leverage risk. However, the equity ratio is high at 84.8%, reflecting a stable asset base primarily funded by equity.

Cash Flow

Ceribell's free cash flow is negative but has shown improvement from 2023. The high operating cash outflows are concerning, relative to the negative net income, indicating cash management issues. A significant financing cash flow in 2024 suggests reliance on external funding to cover operational deficits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	82.81M	65.44M	45.23M	25.92M
Gross Profit	72.87M	56.75M	38.16M	21.49M
EBITDA	-50.78M	-37.32M	-26.51M	-35.06M
Net Income	-52.46M	-40.45M	-29.46M	-37.16M
Balance Sheet
Total Assets	199.53M	225.41M	58.92M	86.46M
Cash, Cash Equivalents and Short-Term Investments	168.54M	194.37M	34.49M	68.23M
Total Debt	21.34M	21.96M	14.20M	18.22M
Total Liabilities	35.44M	34.25M	171.17M	172.86M
Stockholders Equity	164.08M	191.16M	-112.25M	-86.40M
Cash Flow
Free Cash Flow	-41.10M	-36.38M	-30.14M	-32.52M
Operating Cash Flow	-40.16M	-35.04M	-29.16M	-32.00M
Investing Cash Flow	-144.74M	-1.60M	-1.76M	-1.40M
Financing Cash Flow	194.53M	196.52M	-2.82M	49.80M

Ceribell, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.56
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBLL, the sentiment is Negative. The current price of 11.56 is below the 20-day moving average (MA) of 12.30, below the 50-day MA of 12.07, and below the 200-day MA of 16.42, indicating a bearish trend. The MACD of -0.20 indicates Positive momentum. The RSI at 48.71 is Neutral, neither overbought nor oversold. The STOCH value of 42.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CBLL.

Ceribell, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DCTH	58 Neutral	$305.11M	1,004.65	1.94%	―	251.54%	―
BFLY	54 Neutral	$661.82M	-7.83	-41.42%	―	16.04%	28.91%
VREX	52 Neutral	$489.70M	-3.64	-25.57%	―	-1.36%	-479.49%
CTKB	52 Neutral	$580.51M	―	-3.36%	―	-2.18%	-30.96%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CBLL	51 Neutral	$428.83M	―	-59.78%	―	―	―
SRDX	43 Neutral	$393.83M	―	-15.36%	―	-0.02%	-1196.44%

Ceribell, Inc. Corporate Events

Ceribell, Inc. Reports Strong Q3 2025 Revenue Growth

Ceribell, Inc. is a medical technology company specializing in the development of innovative solutions for diagnosing and managing serious neurological conditions, particularly through its point-of-care EEG platform, the Ceribell System. Based in Sunnyvale, California, the company leverages advanced AI-powered algorithms to enhance patient care in acute settings.

Ceribell’s Delirium Study: A New Frontier in EEG Technology

The Ceribell Delirium Data Collection Study aims to enhance the understanding and assessment of delirium subtypes by collecting clinical and rapid response EEG (rrEEG) data. This observational study, officially titled the ‘Ceribell Delirium Data Collection Study,’ is significant for its potential to develop software algorithms that could improve delirium diagnosis and treatment in clinical settings.

Ceribell Expands Supply Chain with New Amendment

Ceribell, Inc. has been working with Shenzhen Everwin Precision Technology Co., Ltd. under a Corporate Supply Agreement initially established in January 2022. This agreement involves the supply of small and large headbands and grants Ceribell broad license rights to necessary product materials. The agreement has undergone several amendments, with the latest Amendment No. 3, dated September 22, 2025, designating Everwin Vietnam as an agent and providing for deliveries from Vietnam. These amendments extend the agreement’s term and expand the company’s operational capabilities, potentially enhancing its market positioning by diversifying its supply chain and production locations.

The most recent analyst rating on (CBLL) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Ceribell, Inc. stock, see the CBLL Stock Forecast page.

Ceribell Appoints Erica Rogers to Board of Directors

On September 17, 2025, Ceribell, Inc. appointed Erica Rogers to its Board of Directors, highlighting her extensive experience in leading high-growth medical device companies. Rogers’ appointment is seen as a strategic move to support Ceribell’s mission to expand nationwide access to its point-of-care EEG system, which has already improved care for critically ill patients in over 550 hospitals. Her leadership is expected to be instrumental in establishing the Ceribell System as the standard of care in acute settings.

The most recent analyst rating on (CBLL) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Ceribell, Inc. stock, see the CBLL Stock Forecast page.

Ceribell, Inc. Faces Financial Uncertainty Amid Trade Policy Shifts and Tariff Challenges

Ceribell, Inc. faces significant business risks due to potential changes in trade policies and regulations in the United States and other countries. The renegotiation or termination of trade agreements, along with the imposition of tariffs, particularly between the U.S. and China, could disrupt their supply chain and increase production costs. Such changes may adversely impact Ceribell’s product sales, gross margins, and customer demand, while also affecting long-term strategies and financial stability. The company’s efforts to mitigate these risks may not be effective, potentially leading to increased capital and operating costs.

Ceribell, Inc. Reports Strong Q2 Growth Amid Challenges

The recent earnings call from Ceribell, Inc. painted a largely positive picture for the company’s future, underscored by robust revenue growth and an optimistic outlook. Despite facing challenges such as increased operating expenses and legal costs, the overall sentiment was upbeat, with the positives significantly outweighing the negatives.

Ceribell, Inc. Reports Strong Q2 2025 Revenue Growth

Ceribell, Inc. is a medical technology company specializing in innovative solutions for diagnosing and managing serious neurological conditions, with its flagship product being the Ceribell System, a point-of-care EEG platform. In its second quarter of 2025, Ceribell reported a significant revenue increase of 38% compared to the previous year, reaching $21.2 million. The company also achieved a gross margin of 88% and expanded its active accounts to 584, reflecting strong commercial performance and adoption of its technology. Key financial metrics reveal a rise in product and subscription revenues, with product revenue at $15.9 million and subscription revenue at $5.3 million, both showing substantial year-over-year growth. However, operating expenses increased by 56% due to investments in commercial expansion and public company operations, resulting in a net loss of $13.6 million. Looking ahead, Ceribell has raised its full-year revenue guidance, anticipating growth between 30% and 34%, as it continues to focus on expanding its market presence and advancing its product pipeline.